| Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer |
| Study Type | Cohort |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
The purpose of this study was to assess the demographics, reasons, methods, perceived benefits, and costs associated with the use of cannabis among patients with cancer. Paper and electronic surveys in English were offered to patients visiting select oncology offices in Northern California between February 2018 and May 2024. Questions gathered information on participants’ demographics, cancer stage, chemotherapy status, methods, and reasons for cannabis use (e.g., appetite, nausea, sleep, pain), symptom severity ratings (1-10) before and after use, and monthly expenditure. Logistic regression analysis was used to compute odds ratios (OR) and 95% confidence intervals (95% CI). Of the 2602 completed surveys, 643 (24.7%) respondents reported using cannabis. Factors significantly associated with use included younger age (OR 0.96; 95% CI 0.95, 0.97), advanced cancer (Stage 4, OR 3.28; 95% CI 1.25, 8.61), and concurrent chemotherapy treatment (OR 2.45; 95% CI 1.80, 3.35). Non-Hispanic White
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.
